SCHEMBL188832

SCHEMBL188832

Nc1ccc(N2CCN(C(=O)CO)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.65
▸ GFER P55789 5/20 0.65
▸ CASP6 P55212 1/20 0.65
▸ MAPT P10636 9/20 0.52
▸ ALDH1A1 P00352 7/20 0.52
▸ GAA P10253 5/20 0.52
▸ LMNA P02545 4/20 0.52
▸ ALOX12 P18054 2/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ KDM4E B2RXH2 3/20 0.50
▸ HTT P42858 2/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ RAD52 P43351 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ ADRA2C P18825 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994240 0.87 GFER (0.61) AKR1C3GFERCASP6MAPTALDH1A1
SCHEMBL15650594 0.86 GFER (0.65) AKR1C3GFERCASP6MAPTALDH1A1
SCHEMBL1813106 0.85 GFER (0.68) GFERCASP6MAPTALDH1A1GAA
SCHEMBL8230222 0.84 MAPT (0.67) GFERCASP6MAPTALDH1A1GAA
SCHEMBL21204377 0.83 AKR1C3 (0.65) AKR1C3MAPTALDH1A1LMNANPSR1
SCHEMBL14924441 0.83 AKR1C3 (0.65) AKR1C3GFERMAPTALDH1A1GAA
SCHEMBL14923989 0.82 AKR1C3 (0.64) AKR1C3GFERCASP6MAPTALDH1A1
SCHEMBL17714306 0.82 ADRA2C (0.54) AKR1C3MAPTALDH1A1LMNAKDM4E
SCHEMBL28806386 0.82 GFER (0.73) AKR1C3GFERCASP6MAPTALDH1A1
SCHEMBL8230438 0.81 MAPT (0.73) GFERCASP6MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 — — US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 — — US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 — — EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 — — WO disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK AKR1C3 205/4885GFER 1162/4885CASP6 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback